Long-acting cat granulocyte macrophage colony stimulating factor recombinant protein, CHO cell expression method and application thereof

The long-acting feline GM-CSF-Fc(L) produced by the CHO cell expression system solves the problems of safety and short half-life of feline GM-CSF products, achieving highly effective treatment of feline leukopenia with significant advantages in efficacy and safety.

CN121779581AActive Publication Date: 2026-04-03HUAZHONG AGRI UNIV
View PDF 7 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-09
Publication Date
2026-04-03

AI Technical Summary

Technical Problem

There is a lack of efficient and safe feline granulocyte-macrophage colony-stimulating factor (GM-CSF) products in the current technology, and the bioactivity and safety of heterologous GM-CSF in cats are difficult to guarantee, resulting in poor treatment effect of feline leukopenia and the need for frequent injections leading to adverse reactions.

Method used

Recombinant cat GM-CSF-Fc(L) was produced using a CHO cell expression system. By linking an HRV 3C restriction site, a flexible linker peptide, and an IgG Fc fragment to the C-terminus of GM-CSF, and further replacing the F at the amino acid terminus with L, a long-acting cat GM-CSF-Fc(L) was formed. Its in vivo half-life was extended using an FcRn-mediated cycling mechanism.

Benefits of technology

It provides a long-acting, safe, and highly effective feline leukocyte-boosting drug that significantly prolongs the half-life of GM-CSF, achieving rapid leukocyte recovery and sustained therapeutic effects, while reducing production costs and injection frequency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention belongs to the technical field of bioengineering, and discloses a long-acting cat granulocyte macrophage colony stimulating factor recombinant protein as well as a CHO cell expression method and application thereof. The cat granulocyte macrophage colony stimulating factor recombinant protein GM-CSF-Fc (L) provided by the invention can show a remarkable curative effect advantage in treatment intervention of cat leucopenia. Besides, the GM-CSF-Fc (L) not only can realize rapid correction of plasma leucocytes, especially neutrophils, of cats suffering from leucopenia within 24 hours after treatment intervention, but also can continuously play a treatment role, and compared with the traditional GM-CSF, the GM-CSF-Fc (L) can remarkably prolong the half-life period, prolong the treatment time and improve the overall prognosis.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Fusion proteins comprising GM-CSF and fc fragment with modified hinge region

    CA2595013A1

  • Multimeric Fc proteins

    CN106068274A

  • Gm-CSF variants and methods of use

    CN109328071A

  • Compositions and methods of use for extending half-life of therapeutic agents in felines

    CN119899259A

  • Long-acting cat omega 2 interferon recombinant protein FeIFN-omega 2-Fc and application

    CN119954968A